Biomerica, Inc.
Biomerica, Inc. (BMRA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
bmra · stock forecast · 3 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Buy
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $2.07
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.97 | ↓ 4.67% |
1-day model range: $1.95–$2. Peak: $2 (-4.67%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -62.5% |
| 2029 | — | -67.2% |
| 2030 | — | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · BMRA · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2020-10-19 | Aegis Capital | Maintains | Buy→Buy |
| 2020-09-04 | Aegis Capital | Maintains | Buy→Buy |
| 2020-08-21 | Aegis Capital | Maintains | Buy→Buy |
| 2018-12-17 | B. Riley Securities | Maintains | Buy→Buy |
| 2018-12-17 | B. Riley FBR | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Biomerica, Inc. (BMRA) stock. Of the recent 5 rating actions, 0 were upgrades and 0 were downgrades. 3 analysts currently cover BMRA.
Analyst Recommendation Trends
BMRA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$8M
↓ 28.5% YoY
Revenue Next Year
$11M
↑ 31.0% YoY
EPS This Year
$-4.24
EPS Next Year
$-3.44
↓ 18.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast BMRA EPS of $-4.24 for the current fiscal year, based on estimates from 1 analysts. The BMRA revenue forecast is $8M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BMRA stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BMRA price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The BMRA short-term stock prediction for tomorrow is $1.97 (-4.67%). The BMRA stock prediction for 2030 projects a range of $1–$1.
Biomerica, Inc. trades on NASDAQ under the ticker BMRA. The BMRA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
BMRA forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month BMRA price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $2.07.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.